Welcome to the WSC 2022 Interactive Program

The congress will officially run on Singapore Standard Time (SGT/UTC+8)

To convert the congress times to your local time Click here

 

*Please note that all sessions in halls Summit 1, Summit 2 & Hall 406 will be live streamed in addition to the onsite presentation


ASK THE SPEAKER
Sessions in Halls 406, Summit 1 and Summit 2 have a Q&A component, through the congress App called “Ask the Speaker”

 

 

Displaying One Session

Session Type
Plenary Session
Date
Wed, 26.10.2022
Session Time
17:15 - 19:15
Room
Hall 406

Opening Performance

Session Type
Plenary Session
Date
Wed, 26.10.2022
Session Time
17:15 - 19:15
Room
Hall 406
Lecture Time
17:15 - 17:25

Opening Address by Chairs

Session Type
Plenary Session
Date
Wed, 26.10.2022
Session Time
17:15 - 19:15
Room
Hall 406
Lecture Time
17:25 - 17:30

Address by The Guest-of-Honor

Session Type
Plenary Session
Date
Wed, 26.10.2022
Session Time
17:15 - 19:15
Room
Hall 406
Lecture Time
17:30 - 17:40

Presentation of Token of Appreciation to The Guest-of-Honor

Session Type
Plenary Session
Date
Wed, 26.10.2022
Session Time
17:15 - 19:15
Room
Hall 406
Lecture Time
17:40 - 17:45

Summary of Virtual Awards (2020 & 2021)

Session Type
Plenary Session
Date
Wed, 26.10.2022
Session Time
17:15 - 19:15
Room
Hall 406
Lecture Time
17:45 - 17:55

RESULTS OF THE TREATMENT EVALUATION OF ACUTE STROKE USING REGENERATIVE CELLS (TREASURE) CLINICAL TRIAL

Session Type
Plenary Session
Date
Wed, 26.10.2022
Session Time
17:15 - 19:15
Room
Hall 406
Lecture Time
17:55 - 18:05

Abstract

Background and Aims

Cell therapy is a promising approach for the treatment of stroke by modulating the immune system. Post-hoc analysis of the MASTERS-1 exploratory trial indicated potential benefits of early treatment with bone marrow-derived, allogenic, clinical-grade multipotent adult progenitor cells (MultiStem®, HLCM051).

The aim of the present multicenter, randomized, double-blind, placebo-controlled, phase 2/3 study (treatment evaluation of acute stroke using regenerative cells: TREASURE) was to verify the benefit of MultiStem® treatment within 36 hours in patients who developed ischaemic stroke.

Methods

Patients aged 20 years or over, who were diagnosed with ischaemic stroke involving the cerebral cortex and had a persistent neurologic deficit corresponding to National Institute of Health Stroke Scale (NIHSS) 8-20, were randomized to treatment with single intravenous infusion of MultiStem® (1200 million cells/patient) or placebo within 18-36 hours of onset.

Primary efficacy outcome is the proportion of patients with excellent outcome at day 90, defined as meeting all the following criteria: modified Rankin Scale (mRS) score 0-1, NIHSS total score 0-1, and Barthel Index score (BI) ≥95. Key secondary outcomes are the proportion of patients with an excellent outcome at day 365 and the distributions of the mRS scores at day 90 and day 365.

Results

Between November 2017 and March 2021, 207 patients (mean age 76.5 years; 54% male) were enrolled at 48 centers in Japan. Median base line NIHSS was 13 and 52% received reperfusion therapy (intravenous thrombolysis or mechanical thrombectomy).

Conclusions

Data analysis is ongoing. Key results will be presented at the World Stroke Congress 2022.

Hide

Q&A

Session Type
Plenary Session
Date
Wed, 26.10.2022
Session Time
17:15 - 19:15
Room
Hall 406
Lecture Time
18:05 - 18:10

EARLY RHYTHM-CONTROL THERAPY FOR ATRIAL FIBRILLATION IN PATIENT WITH HISTORY OF STROKE IN THE EAST-AFNET 4 TRIAL

Session Type
Plenary Session
Date
Wed, 26.10.2022
Session Time
17:15 - 19:15
Room
Hall 406
Lecture Time
18:10 - 18:20

Abstract

Background and Aims

We aimed to test whether early rhythm-control therapy compared to usual care is safe and prevents adverse cardiovascular outcome in patients with history of stroke and atrial fibrillation (AF), first diagnosed within 12 months.

Methods

This prespecified subgroup analysis of the EAST-AFNET 4 trial randomized patients with AF and history of stroke to a systematic strategy of early rhythm-control therapy or usual care. The primary outcome was a composite of death from cardiovascular causes, stroke, or hospitalization with worsening of heart failure or acute coronary syndrome, analysed in a time-to-event analysis. The primary safety outcome was a composite of death, stroke, or serious adverse events related to rhythm-control therapy.

Results

Of 2,784 EAST-AFNET 4 patients, 217 (7.8%) had a history of stroke (mean age 70.5 years, 43.8% women). Of those, 110 (48.5%) were assigned to early rhythm-control and 117 (51.5%) to usual care. A first primary outcome event occurred in 18 of the patients assigned to early rhythm-control (3.7 per 100 person years) and in 33 patients assigned to usual care (7.4 per 100 person-years; hazard ratio 0.52; 95% confidence interval 0.29 to 0.93). A primary safety outcome occurred in 17 (15.5%) patients assigned to early-rhythm control and in 30 (28.0%) patients assigned to usual care. Mortality was lower in patients assigned to early rhythm-control (10.0% vs. 19.6%).

figure_wsc_abstract.png

Conclusions

Among patients with AF and history of stroke, early rhythm-control therapy was associated with a lower risk of adverse cardiovascular outcomes than usual care.

Hide

Q&A

Session Type
Plenary Session
Date
Wed, 26.10.2022
Session Time
17:15 - 19:15
Room
Hall 406
Lecture Time
18:20 - 18:25

FACTOR XIA INHIBITOR MILVEXIAN FOR SECONDARY STROKE PREVENTION: RESULTS OF THE AXIOMATIC-SSP PHASE 2 TRIAL

Session Type
Plenary Session
Date
Wed, 26.10.2022
Session Time
17:15 - 19:15
Room
Hall 406
Lecture Time
18:25 - 18:35

Abstract

Background and Aims

The early risk of stroke remains high in those with symptomatic cerebrovascular disease despite antiplatelet therapy. Reduced FXI activity is associated with lower risk for stroke without increased bleeding. We aimed to estimate the dose-response relationship of milvexian, an oral inhibitor of FXIa, on stroke recurrence and bleeding in patients with acute ischemic stroke or high-risk TIA receiving dual antiplatelet therapy (DAPT).

Methods

In this phase 2 double-blinded, placebo-controlled trial, eligible participants with an ischemic stroke with a NIHSS ≤ 7 or a TIA with an ABCD2 score ≥ 6 or motor symptoms, were randomized within 48 hours of onset to receive one of 5 doses of milvexian or matching placebo for 90 days. All participants received a 300mg loading dose of clopidogrel followed by 75mg for 21 days, and aspirin 100mg for 90 days. MRI was obtained at baseline and 90 days. The primary efficacy endpoint was a composite of ischemic stroke or incident covert infarct on MRI. The main safety endpoint was type 3 or 5 bleeding according to the Bleeding Academic Research Consortium classification.

Results

We randomized 2366 participants from 367 sites in 27 countries. Participants had a median age of 71 years and 64% were male. Most index events (76%) were stroke. The primary end-point occurred in 343/2123 (16%). Final results for all countries will be presented.

Conclusions

AXIOMATIC-SSP is the largest dose-finding trial of an anticoagulant in stroke. The results will inform an assessment of efficacy and safety of milvexian for secondary stroke prevention.

Hide

Q&A

Session Type
Plenary Session
Date
Wed, 26.10.2022
Session Time
17:15 - 19:15
Room
Hall 406
Lecture Time
18:35 - 18:40

EFFECTS OF ORAL FACTOR XIA INHIBITOR ASUNDEXIAN ON INCIDENT COVERT BRAIN INFARCTS ACCORDING TO SIZE, LOCATION AND MULTIPLICITY IN ACUTE NON-CARDIOEMBOLIC ISCHEMIC STROKE: PACIFIC-STROKE TRIAL

Session Type
Plenary Session
Date
Wed, 26.10.2022
Session Time
17:15 - 19:15
Room
Hall 406
Lecture Time
18:40 - 18:50

Abstract

Background and Aims

Background: Covert brain infarcts (CBIs) detected by MRI are more frequent than recurrent ischemic strokes in secondary stroke prevention trials. The effect of the oral factor XIa inhibitor asundexian when added to antiplatelet therapy on incident CBIs among patients with acute non-cardioembolic ischemic stroke was assessed in the PACIFIC-Stroke trial.

Purpose: To report the effects of asundexian, an oral anticoagulant given once daily that directly inhibits factor XIa, on different locations/sizes/multiplicity of incident CBIs.

Methods

Methods: PACIFIC-Stroke (NCT04304508) was an international, double-blind, placebo-controlled, phase II randomized trial involving 1808 participants comparing three dosages of asundexian (BAY 2433334) with placebo. Participants were randomized within 48 hours of the qualifying ischemic stroke, and all received foundation antiplatelet therapy. Participants underwent a study MRI that included required sequences at entry and after 6 months or earlier if study drug was discontinued, with images transferred to a central MRI repository for independent interpretation by two radiologists. Incident CBIs were counted in participants without recurrent ischemic stroke to avoid counting new lesions related to symptomatic infarcts.

Results

Results: The main trial results will be presented at the European Society of Cardiology Conference on August 28th and will be briefly reviewed. New information will be presented about the 1428 (79%) participants with both baseline and follow-up MRIs adequate to assess incident CBIs, including treatment effects according to size, location, and multiplicity of incident CBIs.

Conclusions

Conclusions: Asundexian effects for prevention of different subtypes of CBIs has implications for secondary stroke prevention and is important for design of future trials.

Hide

Q&A

Session Type
Plenary Session
Date
Wed, 26.10.2022
Session Time
17:15 - 19:15
Room
Hall 406
Lecture Time
18:50 - 18:55

Closing by Chairs

Session Type
Plenary Session
Date
Wed, 26.10.2022
Session Time
17:15 - 19:15
Room
Hall 406
Lecture Time
18:55 - 19:00